Linfeng Wu1,2, Gaofu Zhang3,2, Chunbao Guo1,3,4. 1. Chongqing Medical University, Chongqing, China. 2. Department of Nephrology, Children's Hospital, Chongqing Medical University, Chongqing, China. 3. Department of Pediatric General Surgery and Liver Transplantation, Children's Hospital, Chongqing Medical University, Chongqing, China. 4. Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital, Chongqing Medical University, Chongqing, China.
Abstract
BACKGROUND: Thromboelastography (TEG) allows a dynamic assessment of clot formation and dissolution that might be useful for assessing the relative contribution of the coagulation components to overall clot formation and dissolution, but it has not been fully defined in patients with portal cavernoma (PC). METHODS: We retrospectively recruited consecutive patients with PC between July 2006 and June 2016 who had no abdominal malignancy or liver cirrhosis. Blood samples were drawn on admission and were subjected to coagulation parameter assessment, including conventional coagulation tests, measurement of the circulating levels of procoagulant and anticoagulant factors, and TEG assessment. RESULTS: Compared with controls, patients with PC showed significant reductions in the serum levels of procoagulant factors and anticoagulants factors, whereas factor VIII was slightly elevated. TEG showed clot formation (α-angle), and the maximal clot strength (MA) was higher in patients with PC than in controls, indicating a hypercoagulable state. Thrombocytopenia decreased both clot formation (α-angle) and the maximal clot strength (MA) but was still significantly higher than the control. Furthermore, patients with PC had a higher level of D-dimer and LY30 than did controls, indicating the in vivo activation of coagulation and fibrinolysis. CONCLUSION: TEG analysis showed that patients with PC were in a hypercoagulable state that could be partially masked by thrombocytopenia secondary to splenomegaly and hypersplenism in these patients, which indicates that our current prophylaxis and therapy regimen could be improved.
BACKGROUND: Thromboelastography (TEG) allows a dynamic assessment of clot formation and dissolution that might be useful for assessing the relative contribution of the coagulation components to overall clot formation and dissolution, but it has not been fully defined in patients with portal cavernoma (PC). METHODS: We retrospectively recruited consecutive patients with PC between July 2006 and June 2016 who had no abdominal malignancy or liver cirrhosis. Blood samples were drawn on admission and were subjected to coagulation parameter assessment, including conventional coagulation tests, measurement of the circulating levels of procoagulant and anticoagulant factors, and TEG assessment. RESULTS: Compared with controls, patients with PC showed significant reductions in the serum levels of procoagulant factors and anticoagulants factors, whereas factor VIII was slightly elevated. TEG showed clot formation (α-angle), and the maximal clot strength (MA) was higher in patients with PC than in controls, indicating a hypercoagulable state. Thrombocytopenia decreased both clot formation (α-angle) and the maximal clot strength (MA) but was still significantly higher than the control. Furthermore, patients with PC had a higher level of D-dimer and LY30 than did controls, indicating the in vivo activation of coagulation and fibrinolysis. CONCLUSION: TEG analysis showed that patients with PC were in a hypercoagulable state that could be partially masked by thrombocytopenia secondary to splenomegaly and hypersplenism in these patients, which indicates that our current prophylaxis and therapy regimen could be improved.
Authors: Sebastián Raffa; Juan Carlos Reverter; Susana Seijo; Dolors Tassies; Juan G Abraldes; Jaume Bosch; Juan Carlos García-Pagán Journal: Clin Gastroenterol Hepatol Date: 2011-09-23 Impact factor: 11.382
Authors: Paul B Massion; Pierre Peters; Didier Ledoux; Valentine Zimermann; Jean-Luc Canivet; Pierre P Massion; Pierre Damas; André Gothot Journal: Intensive Care Med Date: 2012-06-27 Impact factor: 17.440
Authors: Ara Ko; Megan Y Harada; Galinos Barmparas; Kevin Chung; Russell Mason; Dorothy A Yim; Navpreet Dhillon; Daniel R Margulies; Bruce L Gewertz; Eric J Ley Journal: JAMA Surg Date: 2016-11-01 Impact factor: 14.766